Zoeken
Algemene medische oncologie

Fase I studies bij diverse tumoren

Op deze pagina

Planned

BI 1527-0001

A first-in-human, Phase Ia/Ib, open-label, non-randomized, multi-center dose escalation, and dose expansion trial of BI 3810944 in patients with advanced unresectable or metastatic solid tumors and melanoma.

  • Principal investigator : Prof. Dr. Patrick Schöffski
  • Sponsor : Boehringer Ingelheim
  • More information : 
  • Indication : 
  • Internal reference number : s70876

CA259-0001

A Phase 1, Multicenter, Open-label Study of BMS-986527, Healthy Donor Allogeneic CD70-targeted Chimeric Antigen Receptor (CAR) T Cells, as Monotherapy or in Combination with an Immuno-oncology Agent (Nivolumab) or Tyrosine Kinase Inhibitor (Cabozantinib) in Participants with Clear Cell Renal Cell Carcinoma (ccRCC)

DS1103-074

A Phase 1 randomized study with DS-1103a including dose optimization combined with T-DXd in HER2 Low / Ultra Low unresectable or metastatic Breast cancer. 

INCA036873-101

A Phase 1, Open-Label, Multicenter Study of INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

  • Principal investigator : Prof. Dr. O. Bechter
  • Sponsor : Incyte
  • More information : NCT07195916
  • Indication : Advanced Solid Tumors and Hematological Malignancies
  • Internal reference number : s71510

PANTHA - BAY 22049

A Phase 1 open-label, first-in-human, multi-center study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of 225Ac-PSMA-Trillium in participants with advanced metastatic castration-resistant prostate cancer (mCRPC)

  • Principal investigator : Prof. Dr. H. Dumez
  • Sponsor : Bayer
  • More information : NCT06217822
  • Indication : advanced metastatic castration-resistant prostate cancer (mCRPC)
  • Internal reference number : S71199

SNV4818-101 

A Phase 1 , Open-Label Dose Escalation and Expansion Study of SNV4818 as Monotherapy or in Cmbination With Other Anticancer Agents in Participants With Advanced Solid Tumors 

Ongoing

ADCE-D01

A First-in-human, Phase 1/2, Multicenter, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, PK, and Antitumor activity of ADCE-D01, a Humanized
Anti-human uPARAP Antibody Linked to a Topoisomerase I Inhibitor, in Patients with Metastatic and/or Unresectable Soft Tissue Sarcoma

BI 1456-0001

A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors) 

  • Principal investigator : Prof. Dr. O. Bechter
  • Sponsor : Boehringer Ingelheim
  • More information : 
  • Indication : 
  • Internal reference number : s70284

BEAMION BCGC-1  -  BI1479-0012

Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) in combination with intravenous trastuzumab deruxtecan (T-DXd) or in combination with intravenous trastuzumab emtansine (T-DM1) for treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC)

  • Principal investigator : Prof. Dr. Hans Wildiers
  • Sponsor: Boehringer Ingelheim
  • More information : NCT06324357
  • Indication: HER2+ metastatic + gastric/GEjunction/esophageal
  • Internal reference number : s68772

BP44474 / VVD-133214-01

A phase I, open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of RO7589831 in participants with advanced solid tumors harboring microsatellite instability (MSI) and/or deficient mismatch repair (DMMR)

DS22243-054

Phase 1, Open-Label, Multicenter, First-In-Human Trial of Ds-2243a in Participants With Advanced Solid Tumors

EP102-101

A Phase 1 Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered EP102 monotherapy in Subjects with Advanced Solid Tumors

INCIPIENT

INtra-tumor miCro dosIng in PatIents with advanced malignant mElanoma receiving aNti-PD1 Therapy. A pilot study

  • Principal investigator : Prof. Dr. Oliver Bechter
  • Sponsor : UZ LEUVEN
  • More information : 
  • Indication : Advanced Malignant Melanoma
  • Internal reference number : s68579

MS201460_0001

A Phase 1, Two-Part, Multicenter, Open-Label First in Human Study of anti-GD2 Antibody Drug Conjugate M3554 in Participants with Advanced Solid Tumors

Laatste aanpassing: 25 juni 2026